We appreciate the efforts of Schattner [1] to summarize the evidence from randomized controlled trials regarding the efficacy and safety of colchicine for various emerging indications, which included coronavirus disease 2019 (COVID-19). The four randomized controlled trials [2–5] summarized by Schattner [1] which investigated the use of colchicine in patients with COVID-19 strongly suggesting a beneficial effect of the use of colchicine. Nevertheless, Schattner might have overlooked the recently published RECOVERY trial [6] investigating the use of colchicine in patients with COVID-19 (available as a preprint during the time of his literature search), which is by far the largest randomized trial (n = 11,340) to report the effects of colchicine in patients with COVID-19.
